Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New drugs for NAFLD: lessons from basic models to the clinic
Katharina C. Reimer, Alexander Wree, Christoph Roderburg, et al.
Hepatology International (2019) Vol. 14, Iss. 1, pp. 8-23
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Natascha Roehlen, Émilie Crouchet, Thomas F. Baumert
Cells (2020) Vol. 9, Iss. 4, pp. 875-875
Open Access | Times Cited: 851
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 410
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, et al.
The Lancet (2021) Vol. 399, Iss. 10319, pp. 61-116
Open Access | Times Cited: 170
Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Tobias Puengel, Hanyang Liu, Adrien Guillot, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2668-2668
Open Access | Times Cited: 74
Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression
Adrien Guillot, Marc Winkler, Milessa Silva Afonso, et al.
Hepatology (2023) Vol. 78, Iss. 1, pp. 150-166
Closed Access | Times Cited: 58
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications
Maria Jiménez Ramos, Lucia Bandiera, Filippo Menolascina, et al.
iScience (2021) Vol. 25, Iss. 1, pp. 103549-103549
Open Access | Times Cited: 74
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage
Suling Huang, Yanwei Wu, Zhuohui Zhao, et al.
Metabolism (2021) Vol. 120, pp. 154797-154797
Closed Access | Times Cited: 66
Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
Vera Francisco, María‐Jesús Sanz, José T. Real, et al.
Biology (2022) Vol. 11, Iss. 8, pp. 1237-1237
Open Access | Times Cited: 53
From MAFLD to hepatocellular carcinoma and everything in between
Sarah Da Won Bae, Jacob George, Liang Qiao
Chinese Medical Journal (2022) Vol. 135, Iss. 5, pp. 547-556
Open Access | Times Cited: 46
New Drugs for Hepatic Fibrosis
Liang Shan, Fengling Wang, Dandan Zhai, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 44
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
Tobias Puengel, Sander Lefere, Jana Hundertmark, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6696-6696
Open Access | Times Cited: 43
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Amedeo Lonardo, Stefano Ballestri, Alessandro Mantovani, et al.
Metabolites (2024) Vol. 14, Iss. 1, pp. 40-40
Open Access | Times Cited: 13
The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis
Tobias Puengel, Steve De Vos, Jana Hundertmark, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 4, pp. 1140-1140
Open Access | Times Cited: 63
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 13, pp. 1637-1649
Closed Access | Times Cited: 54
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Eva K. Wirth, Tobias Puengel, Joachim Spranger, et al.
Expert Review of Endocrinology & Metabolism (2022) Vol. 17, Iss. 5, pp. 425-434
Closed Access | Times Cited: 34
Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics
Tanvi Shroff, Kehinde Aina, Christian Maaß, et al.
Open Biology (2022) Vol. 12, Iss. 3
Open Access | Times Cited: 32
Impact of fenofibrate on NAFLD/NASH: A genetic perspective
Ali Mahmoudi, Tannaz Jamialahmadi, Thomas P. Johnston, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 8, pp. 2363-2372
Closed Access | Times Cited: 28
Oxidative stress in metabolic dysfunction‐associated steatotic liver disease (MASLD): How does the animal model resemble human disease?
Patrycja Jakubek, Piotr Kalinowski, Agnieszka Karkucińska‐Więckowska, et al.
The FASEB Journal (2024) Vol. 38, Iss. 3
Open Access | Times Cited: 7
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
Jonathan D. Roth, Sanne Skovgård Veidal, Louise K. D. Fensholdt, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 44
Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway
Jiena Ye, Jiawen Zheng, Xiaoxiao Tian, et al.
Marine Drugs (2022) Vol. 20, Iss. 4, pp. 225-225
Open Access | Times Cited: 26
Chlorogenic acid ameliorated non-alcoholic steatohepatitis via alleviating hepatic inflammation initiated by LPS/TLR4/MyD88 signaling pathway
Xin-Nan Gu, Mengjuan Wei, Feifei Hu, et al.
Chemico-Biological Interactions (2023) Vol. 376, pp. 110461-110461
Closed Access | Times Cited: 15
Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity
Partha Pal, Rajan Palui, Sayantan Ray
World Journal of Hepatology (2021) Vol. 13, Iss. 11, pp. 1584-1610
Open Access | Times Cited: 30
Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes
Jonathan B. Steinman, Marcela Salomao, Utpal B. Pajvani
Liver International (2021) Vol. 41, Iss. 11, pp. 2534-2546
Open Access | Times Cited: 28
Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis
Ali Mahmoudi, Alexandra E. Butler, Muhammed Majeed, et al.
Nutrients (2022) Vol. 14, Iss. 7, pp. 1331-1331
Open Access | Times Cited: 22
Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
Ali Mahmoudi, Seyed Adel Moallem, Thomas P. Johnston, et al.
PPAR Research (2022) Vol. 2022, pp. 1-12
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top